Literature DB >> 32820797

Aldosterone, Inflammation, Immune System, and Hypertension.

Nathanne S Ferreira1, Rita C Tostes2, Pierre Paradis1, Ernesto L Schiffrin1,3.   

Abstract

Aldosterone is a mineralocorticoid hormone that controls body fluid and electrolyte balance. Excess aldosterone is associated with cardiovascular and metabolic diseases. Inflammation plays a critical role on vascular damage promoted by aldosterone and aggravates vascular abnormalities, including endothelial dysfunction, vascular remodeling, fibrosis and oxidative stress, and other manifestations of end-organ damage that are associated with hypertension, other forms of cardiovascular disease, and diabetes mellitus and the metabolic syndrome. Over the past few years, many studies have consistently shown that aldosterone activates cells of the innate and adaptive immune systems. Macrophages and T cells accumulate in the kidneys, heart, and vasculature in response to aldosterone, and infiltration of immune cells contributes to end-organ damage in cardiovascular and metabolic diseases. Aldosterone activates various subsets of innate immune cells such as dendritic cells and monocytes/macrophages, as well as adaptive immune cells such as T lymphocytes, and, by activation of mineralocorticoid receptors stimulates proinflammatory transcription factors and the production of adhesion molecules and inflammatory cytokines and chemokines. This review will briefly highlight some of the studies on the involvement of aldosterone in activation of innate and adaptive immune cells and its impact on the cardiovascular system. Since aldosterone plays a key role in many cardiovascular and metabolic diseases, these data will open up promising perspectives for the identification of novel biomarkers and therapeutic targets for prevention and treatment of diseases associated with increased levels of aldosterone, such as arterial hypertension, obesity, the metabolic syndrome, and heart failure.
© The Author(s) 2020. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.

Entities:  

Keywords:  adaptive immune response; blood pressure; dendritic cells; hypertension; inflammation; innate immune response; lymphocytes; mineralocorticoid receptor; monocytes/macrophages

Year:  2021        PMID: 32820797     DOI: 10.1093/ajh/hpaa137

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  21 in total

Review 1.  Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.

Authors:  Scott Cohen; Hillel Sternlicht; George L Bakris
Journal:  Curr Diab Rep       Date:  2022-04-20       Impact factor: 4.810

2.  Splenocyte transfer from hypertensive donors eliminates premenopausal female protection from ANG II-induced hypertension.

Authors:  Megan A Sylvester; Dennis P Pollow; Caitlin Moffett; Wendy Nunez; Jennifer L Uhrlaub; Janko Nikolich-Zugich; Heddwen L Brooks
Journal:  Am J Physiol Renal Physiol       Date:  2022-01-10

Review 3.  Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.

Authors:  Nasim Bolouri; Maryam Akhtari; Elham Farhadi; Reza Mansouri; Seyedeh Tahereh Faezi; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Inflamm Res       Date:  2022-03-17       Impact factor: 4.575

Review 4.  Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Authors:  Jonatan Barrera-Chimal; Ixchel Lima-Posada; George L Bakris; Frederic Jaisser
Journal:  Nat Rev Nephrol       Date:  2021-10-21       Impact factor: 28.314

5.  Circadian Variation of Blood Pressure in Patients with Chronic Musculoskeletal Pain: A Cross-Sectional Study.

Authors:  Santiago Navarro-Ledesma; Ana Gonzalez-Muñoz; Maria Carmen García Ríos; Daniel de la Serna; Leo Pruimboom
Journal:  Int J Environ Res Public Health       Date:  2022-05-26       Impact factor: 4.614

Review 6.  Hypertensive eye disease.

Authors:  Carol Y Cheung; Valérie Biousse; Pearse A Keane; Ernesto L Schiffrin; Tien Y Wong
Journal:  Nat Rev Dis Primers       Date:  2022-03-10       Impact factor: 52.329

7.  DNA methylation changes following narrative exposure therapy in a randomized controlled trial with female former child soldiers.

Authors:  Samuel Carleial; Daniel Nätt; Eva Unternährer; Thomas Elbert; Katy Robjant; Sarah Wilker; Vanja Vukojevic; Iris-Tatjana Kolassa; Anja C Zeller; Anke Koebach
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.379

8.  Integrated multi-omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer.

Authors:  Jialin Meng; Xiaofan Lu; Chen Jin; Yujie Zhou; Qintao Ge; Jun Zhou; Zongyao Hao; Fangrong Yan; Meng Zhang; Chaozhao Liang
Journal:  Clin Transl Med       Date:  2021-12

Review 9.  Vascular Stress Signaling in Hypertension.

Authors:  Stephanie M Cicalese; Josiane Fernandes da Silva; Fernanda Priviero; R Clinton Webb; Satoru Eguchi; Rita C Tostes
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

10.  Clinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism.

Authors:  Daisuke Watanabe; Satoshi Morimoto; Noriko Morishima; Atsuhiro Ichihara
Journal:  Endocr Connect       Date:  2021-06-08       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.